Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.54 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293459 | 0.88 | LMNA (0.54) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL4300481 | 0.84 | LMNA (0.53) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL4293954 | 0.84 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL431539 | 0.81 | CYP3A4 (0.56) | LMNAMEN1POLBKMT2AALDH1A1 | |
| SCHEMBL13957595 | 0.76 | CYP3A4 (0.54) | LMNAMEN1POLBKMT2AALDH1A1 | |
| SCHEMBL4288723 | 0.75 | THRA (0.42) | S1PR1S1PR3S1PR4S1PR5LMNA | |
| SCHEMBL4288725 | 0.74 | SPHK1 (0.46) | S1PR1S1PR3S1PR4THRATHRB | |
| SCHEMBL4291335 | 0.74 | S1PR1 (0.49) | S1PR1S1PR3S1PR4S1PR5THRA | |
| SCHEMBL5797072 | 0.74 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL4300178 | 0.74 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | S1PR1 2/4885S1PR3 4/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.